SRGN and plasma cell myeloma: In a recent study, we demonstrated that CS chains with specific structure present on serglycin isolated from myeloma cells inhibited the classical complement pathway through direct binding to C1q, whereas the overall structure of serglycin was involved in the binding of MBL and the inhibition of the lectin pathway [13].